Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.

HACKENSACK, NJ – May 30, 2019  –  Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.

Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019

 Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.

Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.  AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly knowledgeable and conscientious Institutional Animal Care and Use Committee.

Expects Revenue Growth of at Least 20% for Fiscal Year 2019

Hackensack, NJ – July 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2018.

Hackensack, NJ – June 18, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.

HACKENSACK, N.J., - May 3, 2018 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith’s offices located at 599 Lexington Avenue.

Experienced Scientist to Lead Immuno-Oncology Research, Driving Significant Expansion of Market Opportunity

Hackensack, NJ – May 1, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.

Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.

Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018

Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.